Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
opioid dependence
Pharma
Alkermes grants Teva license to launch generic Vivitrol in 2027
Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.
Zoey Becker
Aug 31, 2023 10:05am
FDA clears Braeburn's Brixadi to treat opioid use disorder
May 24, 2023 10:44am
Love Pharma moves to buy transdermal opioid-use disorder player
Oct 18, 2022 9:20am
Califf reveals new FDA framework to study opioid crisis
Aug 31, 2022 9:47am
In low-key restructuring, Trevena lays off 25% of its staff
Jul 28, 2022 6:46pm
A judge denied Teva's motion to delay a CA opioid suit
Feb 24, 2022 1:01pm